• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

FLUPENTIXOL Drug Record

  • Summary
  • Interactions
  • Claims
  • FLUPENTIXOL chembl:CHEMBL54661

    Alternate Names:

    LC-44
    FLUPENTIXOL
    N-7009
    FLUPENTHIXOL
    ALPHA-FLUPENTHIXOL
    CIS FLUPENTHIXOL
    drugbank:00875
    chembl:CHEMBL54661
    chemidplus:53772-82-0
    pubchem.compound:5281881

    Drug Info:

    (0 More Sources)

    Publications:

    Reimold et al., 2007, Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol., Psychopharmacology (Berl.)
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Cai et al., 1999, Inverse agonist properties of dopaminergic antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A) dopamine receptor from G(s) protein., Mol. Pharmacol.
    Arnt, 1995, Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine., Eur. J. Pharmacol.
    Nilsson et al., 1996, Inverse agonism at dopamine D2 receptors. Haloperidol-induced prolactin release from GH4C1 cells transfected with the human D2 receptor is antagonized by R(-)-n-propylnorapomorphine, raclopride, and phenoxybenzamine., Neuropsychopharmacology
    Ogren et al., 1984, Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain., Eur. J. Pharmacol.
    Seeman, 2002, Atypical antipsychotics: mechanism of action., Can J Psychiatry
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Huettl et al., 1991, Effects of dopamine receptor agonists and antagonists on catecholamine release in bovine chromaffin cells., J. Pharmacol. Exp. Ther.
    Tresadern G et al., 2011, Molecular properties affecting fast dissociation from the D2 receptor., Bioorg Med Chem
  • FLUPENTIXOL   DRD2

    Interaction Score: 0.67

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    7498321 8797192 6149133 11873706 11752352 1674528 17111172 21421319


    Sources:
    DTC

  • FLUPENTIXOL   DRD1

    Interaction Score: 0.4

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    17111172 17016423 17139284 10531405


    Sources:
    DTC

  • FLUPENTIXOL   CBX1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • FLUPENTIXOL   USP1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • FLUPENTIXOL   ATXN2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DTC: FLUPENTIXOL

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL54661 ChEMBL Drug ID

    Drug Info:

    Publications:
    Tresadern G et al., 2011, Molecular properties affecting fast dissociation from the D2 receptor., Bioorg Med Chem

  • ChemblDrugs: chembl:CHEMBL54661

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21